Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could parsley and rosemary ease endometriosis pain?

NCT ID NCT07228975

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a dietary supplement made from parsley, rosemary, selenium, and vitamins in 36 women with endometriosis. The goal was to see if it could reduce pain and the need for NSAIDs. The supplement was taken daily for a period, and pain levels were measured using a standard scale.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dietary supplement containing parsley extract, rosemary extract, selenium, mountain celery, and vitamins B6, D, and E
What this could lead to
If it works, this could offer a natural option to help manage endometriosis pain and reduce reliance on painkillers.
What could go wrong
This is a very small pilot study with only 36 participants and no placebo group, so results may not be reliable or apply to everyone. Dietary supplements are not strictly regulated like drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Sep 2024

Finished

Jul 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for the Initial Run-In Phase 1. Written informed consent, signed and dated personally by the patient. 2. Female between the ages of 18 and 45 (including limits), with no race limitation. 3. Documented endometriosis, confirmed by laparoscopy, ultrasound, or MRI, with or without biopsy, performed up to 36 months prior to the start of this investigation and independently of it. 4. Stable health condition and stable drug treatments within the past 2 months. 5. Endometriosis with a grade 2 (mild) to grade 4 (severe) AFSr score, whether or not treated with sex hormones, contraceptives, or any other specific treatment, stable for a minimum of 2 months. Note: In a first phase of the investigation, patients in class 2 and 3 will be recruited, while in a second phase, patients in class 4 will also be recruited. 6. 10-point Visual Analogue Scale (VAS) score of pain due to endometriosis of at least 4 for at least 2 days in the 4 weeks prior to run-in. Inclusion criteria for treatment initiation Patients will start treatment with EndOK Green if they meet all of the following criteria. 1. Negative urine pregnancy test. 2. Difference, for at least two days, of no more than 10 in the 10-point Visual Analogue Scale (VAS) (10%) between the 4 weeks prior to the screening visit and the end of the run-in phase, provided that at least one menstruation occurred in the period. 3. No change in background therapy. Exclusion Criteria Patients will be excluded if they meet even one of the following criteria: 1. Pregnancy, breastfeeding, or intending to become pregnant during the time this investigation will be conducted. 2. Absence of cycles for at least 3 months. 3. Previous hysterectomy or oophorectomy. 4. Pelvic inflammatory disease regardless of its etiology (Chlamydia Trachomatis, Neisseria gonorrhoeae, fungi, etc.) or presence of ovarian cysts. 5. Known hypersensitivity or allergy to the active substances and/or any component of the product under investigation. 6. Patient who has taken, within 4 weeks prior to inclusion, or is currently taking, dietary supplements for the treatment of pelvic pain or other symptoms of endometriosis. 7. Participation in any clinical study that has been ongoing or concluded for less than three months. 8. Patient with one or more psychiatric disorders, such as alcoholism, substance abuse or addictive disorder, bipolar disorder, schizophrenia, or other personality disorders. 9. Patient who, in the opinion of the gynecologist, will not be able to meet the prerequisites required for this investigation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometriosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Site#1 - Via Europa, 67

    Alzano Lombardo, BG, 24022, Italy

  • Site#2 - Borgo Sant'Agnese, 93

    Portogruaro, VE, 30026, Italy

  • Site#3 - Via Enrico De Nicola, 171

    Camaiore, LU, 55041, Italy

  • Site#4 - Via Nicola Tridente, 35

    Bari, BA, 70125, Italy

  • Site#5 - Via Sabbionera, 45

    Latisana, UD, 33053, Italy

  • Site#6 - Capo di piazza Gianni Bartoli, 1

    Trieste, TS, 34100, Italy

  • Site#7 - Via S.Maria del Pozzo, 106

    Somma Vesuviana, 80049, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.